Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study monitors lung side effects of cancer drug brigatinib

NCT ID NCT05100069

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study is a survey in Japan of the drug Brigatinib for people with a specific type of non-small cell lung cancer. The main goal is to check for lung-related side effects over one year. About 500 participants will take the drug as part of their normal care, and doctors will record any health issues. This is not a cure, but a way to better understand the drug's safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Takeda Selected Site

    RECRUITING

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NSCLC NON-SMALL CELL LUNG CANCER (NSCLC)